Abstract
IT has recently been observed that patients with Duchenne muscular dystrophy (DMD) have a significant defect in the uptake of serotonin (5-HT) into platelets1, raising the possibility that a defect in the metabolism of biogenic amines may be important in the pathogenesis of the skeletal muscle lesions of this disorder. If monoamines such as 5-HT or norepinephrine (NE) which are dependent on the intracellular enzyme, monoamine oxidase (MAO), have a diminished ability to reach this site of metabolism, increased tissue levels of these compounds could result and produce skeletal muscle damage. The effect of such a defect would be enhanced in skeletal muscle as catechol-O-methyltransferase, the alternative pathway for metabolism of biogenic amines, is absent from this tissue2. Support for this hypothesis of skeletal muscle damage is found in the observation that skeletal muscle from biopsies of Duchenne dystrophy patients has shown the presence of an abnormal intrafibrillar fluorescence (Falck-Hillarp technique) presumed to be a monoamine-like substance3. Furthermore, injection of the MAO inhibitor, pargyline, results in a myopathy with evidence for accumulation of monoamines4. The pargyline induced myopathy, however, has serious limitations as a model for Duchenne dystrophy, as the lesions are limited to the soleus muscle and, furthermore, MAO activity has been found to be normal in patients with DMD (ref. 1).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Murphy, D. L., Mendell, J. R., and Engel, W. K., Arch. Neurol., 28, 239 (1973).
The Pharmacologic Basis of Therapeutics (edit. by Goodman, L. S., and Oilman, A.), 427 (Macmillan, New York, 1965).
Wright, T. L., O'Neill, J. A., and Olson, W. H., Neurology (Minneap.), 23, 407 (1973).
Yu, M. K., Wright, T., Dettbarn, W., and Olson, W. H., Neurology (Minneap.) (1973).
Murphy, D. L., and Kopin, I. J., in Cell Transport and Metabolism (edit. by Hokin, L. E.), 503 (Academic Press, New York, 1972).
Engel, W. K., and Brooke, M. H., in Neurological Diagnostic Techniques (edit. by Fields, W. S.), 90 (Thomas, Springfield, Illinois, 1966).
Mendell, J. R., Engel, W. K., and Derrer, E. C., Science, N.Y., 172, 1143 (1971).
Hathaway, P. W., Engel, W. K., and Zellweger, H., Arch Neurol., 22, 365 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
PARKER, J., MENDELL, J. Proximal Myopathy induced by 5-HT-Imipramine simulates Duchenne Dystrophy. Nature 247, 103–104 (1974). https://doi.org/10.1038/247103b0
Received:
Issue Date:
DOI: https://doi.org/10.1038/247103b0
This article is cited by
-
Oxidative stress in muscular dystrophy: from generic evidence to specific sources and targets
Journal of Muscle Research and Cell Motility (2014)
-
Experimental serotonin myopathy as an animal model of muscle degeneration and regeneration in muscular dystrophy
Acta Neuropathologica (1991)
-
The influence of ketanserin, a new S2 receptor antagonist on experimentally induced skeletal muscle myopathy in the rat
Virchows Archiv A Pathological Anatomy and Histology (1981)
-
The pattern of urinary catecholamines and their metabolites in Duchenne myopathy, in relation to disease evolution
Journal of Neural Transmission (1979)
-
Increased axoplasmic flow associated with pargyline under conditions which induce a myopathy
Nature (1975)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.